Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2021-07-08 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
TEZEPELUMAB GRANTED FDA PRIORITY REVIEW FOR ASTHMA
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It contains detailed information about the FDA Priority Review granted to the drug tezepelumab for asthma, including clinical trial results, regulatory status, and collaboration details. Form 6-K filings are typically used by foreign private issuers to report material information that is not required to be filed on Forms 20-F or 40-F. This document is not an annual report, earnings release, or any other specific financial report but rather a regulatory filing providing material news and updates. Therefore, it fits best under the category of Regulatory Filings (RNS). The document length is substantial (15,000 characters), and it contains substantive information rather than just an announcement or certification, supporting this classification with high confidence.
2021-07-08 English
Tezepelumab granted FDA Priority Review for asthma
Regulatory Filings Classification · 100% confidence The document is a formal announcement released via RNS (RNS Number : 5408E) on July 8, 2021. The content details a significant regulatory event: the FDA's acceptance and granting of Priority Review for AstraZeneca's Biologics License Application (BLA) for tezepelumab for asthma treatment. This is a specific, material corporate event announcement concerning regulatory progress and clinical trial data (NAVIGATOR, SOURCE). It is not a full Annual Report (10-K), an Interim Report (IR), or a general Earnings Release (ER). It is a specific regulatory/corporate update. Since it is a formal, time-sensitive announcement of a material event (FDA action), and it is distributed via RNS, it fits best under the general 'Regulatory Filings' category (RNS) as a specific regulatory update, although it contains elements of R&D/Clinical news. Given the options, RNS serves as the appropriate catch-all for specific, non-standard regulatory/exchange announcements that aren't covered by the other specific codes (like DIRS, DIV, etc.). The document length (17k chars) is substantial, suggesting it is the primary announcement itself, not just a brief notice of publication (RPA).
2021-07-08 English
ASTRAZENECA-ALEXION TRANSACTION CLEARED IN THE EU
M&A Activity Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. The content focuses on the announcement of regulatory clearance from the European Commission for AstraZeneca's proposed acquisition of Alexion Pharmaceuticals. It includes details about the transaction status, regulatory approvals, and forward-looking statements related to the acquisition. There are no financial statements or detailed financial performance data presented. The document is primarily an announcement related to a merger and acquisition activity, specifically about regulatory clearance and progress towards completing the acquisition. Given the nature of the content and the form type (6-K), this filing best fits the category of M&A Activity (TAR), which covers announcements and documents related to merger proposals or takeover bids.
2021-07-06 English
AstraZeneca-Alexion transaction cleared in the EU
Regulatory Filings Classification · 98% confidence The document is an official announcement released via RNS (RNS Number : 2430E) on July 6, 2021. The content explicitly discusses the receipt of clearance from the European Commission for the proposed acquisition of Alexion Pharmaceuticals, Inc. This is a significant corporate event related to M&A activity. While it mentions regulatory filings (like the Form F-4 filed with the SEC), the primary purpose of this specific document is to announce the progress and status of the acquisition, which falls under Merger & Acquisition (M&A) activity. The definition for M&A Activity is 'Announcements and documents related to merger proposals or takeover bids' (Code: TAR). Since this is a formal announcement of a major transaction milestone, TAR is the most appropriate classification over the general 'RNS' fallback, although it is distributed via RNS.
2021-07-06 English
425 Filing
Merger & Acquisition Classification · 95% confidence The document is filed by AstraZeneca PLC pursuant to Rule 425 under the United States Securities Act of 1933. It references the proposed acquisition of Alexion Pharmaceuticals, Inc. and mentions the filing of a Form F-4 registration statement and proxy statements related to the acquisition. The document includes forward-looking statements and directs investors to read the registration statement and proxy materials filed with the SEC. The content is focused on merger communications and acquisition-related disclosures. Rule 425 filings are specifically used for merger communications and are distinct from proxy statements or registration statements themselves. Given the references to Rule 425 and the nature of the content, this document is best classified under Merger & Acquisition (MA).
2021-07-06 English
425 Filing
Merger & Acquisition Classification · 95% confidence The document is a communication filed pursuant to Rule 425 under the US Securities Act of 1933, related to the AstraZeneca proposed acquisition of Alexion Pharmaceuticals. It includes regulatory clearance updates, references to SEC filings such as Form F-4 and proxy statements, and forward-looking statements about the acquisition. The document is an announcement about the progress and regulatory clearances of a merger/acquisition transaction, not the merger proxy statement itself or a full merger filing. It is not a full financial report, earnings release, or management discussion. The presence of Rule 425 filing and the nature of the content indicate this is related to merger communications. Therefore, the document fits best under the category of Merger & Acquisition (MA).
2021-07-06 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.